Public Pharma for Europe: The Case of CAR-T Cell Therapy

On far too many occasions, publicly funded medical research that leads to successful health technologies fails to prioritize global access in licensing and marketing strategies. As public research institutions lead the development of CAR-T therapies, these groundbreaking therapies offer a new opportunity for the public sector to contribute to more globally equitable and just pharmaceutical policies.

Hear from researchers, advocates, and academics as we address the main challenges to scaling up CAR-T therapies’ development and production in the public sector.